● Recruiting

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Condition: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) · Sponsor: Novartis Pharmaceuticals

PhasePhase 1/Phase 2

Planned participants181

Who can joinMale, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com

Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com

Always discuss trial participation with your own doctor first.

Locations (31)

Univ of Alabama at Birmingham	Birmingham, Alabama, United States	Recruiting
Uni Of Iowa Hospitals And Clinics	Iowa City, Iowa, United States	Recruiting
University of Kansas Cancer Center	Westwood, Kansas, United States	Recruiting
Wichita Urology Group PA	Wichita, Kansas, United States	Recruiting
Duke University Medical Center	Durham, North Carolina, United States	Recruiting
Medical University of South Carolina MUSC	Charleston, South Carolina, United States	Recruiting
Carolina Urologic Research Center	Myrtle Beach, South Carolina, United States	Recruiting
Huntsman Cancer Institute	Salt Lake City, Utah, United States	Recruiting
Novartis Investigative Site	Camperdown, New South Wales, Australia	Withdrawn
Novartis Investigative Site	Wollongong, New South Wales, Australia	Recruiting
Novartis Investigative Site	Porto Alegre, Rio Grande do Sul, Brazil	Recruiting
Novartis Investigative Site	Montreal, Quebec, Canada	Recruiting

+ 19 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07190300